William Blair & Company
ADAP

William Blair & Company’s Adaptimmune Therapeutics ADAP Stock Holding History

William Blair & Company’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,000
Closed -$207K – 1962
2021
Q3 		$207K Buy
+40,000
New +$179K ﹤0.01% 1482

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair & Company's ADAP Position: Q4 2021 in Review

William Blair & Company sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 40,000 shares — an estimated $207K sold.

William Blair & Company first reported a position in ADAP in Q3 2021 and held it in 1 quarter. The position peaked at $207K in Q3 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

  • William Blair & Company reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
  • William Blair & Company sold 40,000 Adaptimmune Therapeutics shares in Q4 2021, an estimated $207K.
  • William Blair & Company first reported a position in Adaptimmune Therapeutics in Q3 2021 and held it in 1 quarter.
  • William Blair & Company's Adaptimmune Therapeutics position peaked at $207K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on William Blair & Company's 13F filing for Q4 2021, filed 14 Feb 2022.